Ocular Therapeutix (OCUL) Liabilities and Shareholders Equity (2013 - 2026)
Ocular Therapeutix's quarterly Liabilities and Shareholders Equity came in at $732.5 million in Q1 2026, up 80.46% year-on-year from $405.9 million in Q1 2025, and down 9.35% quarter-over-quarter from $808.1 million in Q4 2025.
Ocular Therapeutix has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $732.5 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 80.46% year-over-year to $732.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 billion (up 28.4% YoY), and the FY2025 full-year result was $808.1 million, up 76.46% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $732.5 million, down from $808.1 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $808.1 million in Q4 2025, with the low at $122.6 million in Q2 2023.
- Average Liabilities and Shareholders Equity over 5 years is $361.6 million, with a median of $405.9 million recorded in 2025.
- Year-over-year, Liabilities and Shareholders Equity plunged 31.47% in 2023 and surged 321.92% in 2024.
- Tracing OCUL's Liabilities and Shareholders Equity over 5 years: stood at $149.3 million in 2022, then jumped by 68.84% to $252.1 million in 2023, then soared by 81.68% to $457.9 million in 2024, then surged by 76.46% to $808.1 million in 2025, then slipped by 9.35% to $732.5 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $732.5 million (Q1 2026), $808.1 million (Q4 2025), and $410.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 732.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 732.53 Mn |
| Dec 31, 2025 | 808.06 Mn |
| Sep 30, 2025 | 410.88 Mn |
| Jun 30, 2025 | 451.33 Mn |
| Mar 31, 2025 | 405.92 Mn |
| Dec 31, 2024 | 457.94 Mn |
| Sep 30, 2024 | 490.37 Mn |
| Jun 30, 2024 | 517.09 Mn |
| Mar 31, 2024 | 538.95 Mn |
| Dec 31, 2023 | 252.06 Mn |
| Sep 30, 2023 | 162.38 Mn |
| Jun 30, 2023 | 122.56 Mn |
| Mar 31, 2023 | 128.57 Mn |
| Dec 31, 2022 | 149.29 Mn |
| Sep 30, 2022 | 158.58 Mn |
| Jun 30, 2022 | 173.07 Mn |
| Mar 31, 2022 | 187.62 Mn |
| Dec 31, 2021 | 204.89 Mn |
| Sep 30, 2021 | 217.74 Mn |
| Jun 30, 2021 | 230.71 Mn |
| Mar 31, 2021 | 243.04 Mn |
| Dec 31, 2020 | 261.86 Mn |
| Sep 30, 2020 | 98.22 Mn |
| Jun 30, 2020 | 107.26 Mn |
| Mar 31, 2020 | 72.86 Mn |
| Dec 31, 2019 | 78.74 Mn |
| Sep 30, 2019 | 88.71 Mn |
| Jun 30, 2019 | 89.74 Mn |
| Mar 31, 2019 | 101.49 Mn |
| Dec 31, 2018 | 73.04 Mn |
| Sep 30, 2018 | 70.27 Mn |
| Jun 30, 2018 | 70.46 Mn |
| Mar 31, 2018 | 76.69 Mn |
| Dec 31, 2017 | 55.43 Mn |
| Sep 30, 2017 | 64.40 Mn |
| Jun 30, 2017 | 79.68 Mn |
| Mar 31, 2017 | 90.70 Mn |
| Dec 31, 2016 | 74.94 Mn |
| Sep 30, 2016 | 82.35 Mn |
| Jun 30, 2016 | 89.90 Mn |
| Mar 31, 2016 | 100.43 Mn |
| Dec 31, 2015 | 110.31 Mn |
| Sep 30, 2015 | 119.32 Mn |
| Jun 30, 2015 | 129.47 Mn |
| Mar 31, 2015 | 71.50 Mn |
| Dec 31, 2014 | 78.19 Mn |
| Sep 30, 2014 | 83.88 Mn |
| Jun 30, 2014 | 23.97 Mn |
| Dec 31, 2013 | 19.15 Mn |